PMC10214075_01
Physical activity (PA) and moderate to vigorous physical activity (mvPA).
: diagnosis;
: chemotherapy
FOLFIRINOX course; :
surgery.
10.1177_20552076231177127-fig1.jpg
PMC10214075_01_10.1177_20552076231177127-fig1.jpg
fig1-20552076231177127
PA and mvPA declined after the onset of symptoms in November '20, increased in March '21 (without chemotherapy and before surgery), then declined after surgery and then gradually increased; mvPA increased above baseline values after the end of treatment (Figure 1).
Estimated maximal oxygen uptake (est. VO2max). : diagnosis; : chemotherapy FOLFIRINOX course;
: surgery.
10.1177_20552076231177127-fig2.jpg
PMC10214075_01_10.1177_20552076231177127-fig2.jpg
fig2-20552076231177127
Est.VO2max remained stable from baseline until surgery the end of March '21, then decreased, recovered somewhat in May '21-June '21 and remained stable from July '21 until March '22 and recovered until baseline from April '22 to July '22 (Figure 2).
Heart rate variability (HRV) and heart rate frequency at rest (hRrest). : diagnosis; : chemotherapy FOLFIRINOX course;
: surgery.
10.1177_20552076231177127-fig3.jpg
PMC10214075_01_10.1177_20552076231177127-fig3.jpg
fig3-20552076231177127